Tryptamine Compound Compositions for REM and Non-REM Sleep Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapies that can reduce REM sleep and/or non-REM sleep in patients suffering from sleep disorders or dysfunctional sleep associated with other conditions or diseases.
Innovation Solution
The use of compounds of Formula (I), which can be administered to a subject to reduce REM sleep and/or non-REM sleep, is disclosed. These compounds include specific structural elements such as various alkyl, haloalkyl, heterocycle, and halogen groups, and can be used to treat sleep dysfunction, stress-related disorders, neuropsychiatric diseases, and neurodevelopmental disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional sleep therapies are used, then sleep duration is maintained or increased, but REM sleep and non-REM sleep cannot be adequately reduced in patients with sleep disorders
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of tryptamine compounds to create derivatives with specific pharmacological properties. The compounds of Formula (I) and Formula (II) represent systematic variations in molecular parameters (substituents R1-R13) that enable selective reduction of REM and non-REM sleep while maintaining therapeutic effectiveness for various sleep disorders.
2Duration of action of moving object
If sleep duration is increased to treat insomnia, then sleep quantity improves, but REM sleep reduction capability is lost
Solution Approach 1:
The patent applies local quality by designing compounds that selectively affect specific sleep stages (REM and non-REM) while preserving overall sleep architecture. The tryptamine derivatives exhibit stage-specific modulatory effects, allowing reduction of pathological REM sleep without compromising total sleep duration or quality of essential sleep stages.
Solution Approach 2:
The invention utilizes dynamics by creating compounds that can adaptively modulate sleep stages based on individual patient needs and disorder characteristics. The compounds dynamically adjust REM and non-REM sleep proportions rather than uniformly suppressing all sleep, enabling flexible treatment of various sleep dysfunctions.
3Reliability
If traditional treatments are applied, then general sleep quality is maintained, but specific sleep stage regulation (REM reduction) is not achieved
Solution Approach 1:
The patent achieves precise sleep stage control through parameter changes in compound structure. The specific molecular configurations of Formula (I) and Formula (II) compounds enable selective interaction with neurotransmitter systems regulating REM sleep, providing precise modulation of sleep architecture while maintaining overall sleep quality.
Data Source
AI summary
Provided herein are compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (I-A), Formula (I-B) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), Formula (I-A), Formula (I-B) or pharmaceutically acceptable salt thereof. The current invention reports compounds to reduce REM sleep and/or non-REM sleep in a subject which can be effective in treating diseases or disorder where sleep is dysregulated. The methods of the disclosure include methods of treating sleep dysfunction, sleep disorder, stress related disorders, neuropsychiatric diseases, neurological conditions and/or neurodevelopmental disorders, using the compound of Formula (I), Formula (I-A), and/or Formula (I-B).